Search results for " Pituitary"

showing 10 items of 51 documents

Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior

2019

Although generally benign, pituitary tumors frequently show local invasiveness and resistance to pharmacological therapy. After the demonstration of the existence of pituitary gland stem cells, over the past decade, the presence of a stem cell subpopulation in pituitary tumors has been investigated, analogous to the cancer stem cell model developed for malignant tumors. This review recapitulates the experimental evidence supporting the existence of a population of stem-like cells in pituitary tumors, focusing on their potential role in tumor initiation, progression, recurrence and resistance to pharmacological therapy.

0301 basic medicinePituitary glandrecurrencePharmacological therapyMini ReviewEndocrinology Diabetes and MetabolisminvasivenessPopulation030209 endocrinology & metabolismTumor initiationmedicine.disease_causelcsh:Diseases of the endocrine glands. Clinical endocrinologyresistance03 medical and health sciences0302 clinical medicineEndocrinologyCancer stem cellpituitary tumorsstem cellsmedicineeducationinvasiveness; pituitary tumors; recurrence; resistance; stem cells; tumourigenesiseducation.field_of_studylcsh:RC648-665business.industryPituitary tumorsmedicine.disease030104 developmental biologymedicine.anatomical_structuretumourigenesisCancer researchStem cellCarcinogenesisbusinessFrontiers in Endocrinology
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

2018

Purpose To establish a simplified three-dimensional (3D) meibomian gland culture model using a meibomian gland epithelial cell (HMGEC) line that might be a useful tool to gain deeper insights into meibomian gland dysfunction. For this purpose, 3D differentiation patterns and growth characteristics of HMGECs were studied on various membranes/scaffolds as well as in hanging drops. Methods Several types of inserts consisting of different materials (Millicell-HA, Millicell-PCF, ThinCert, and Alvetex) as well as hanging drop culture were analyzed. Culture conditions were optimized employing exposure to air (air-lift) and different cell culture media for a maximum of 28 days. To characterize cell…

0301 basic medicinechemistry.chemical_classificationChemistryCellular differentiationMeibomian glandCell biology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureEpidermal growth factorCell cultureKeratin030221 ophthalmology & optometryUltrastructuremedicineBovine Pituitary ExtractKeratinocyteInvestigative Opthalmology & Visual Science
researchProduct

Optogenetically enhanced pituitary corticotroph cell activity post-stress onset causes rapid organizing effects on behaviour

2016

The anterior pituitary is the major link between nervous and hormonal systems, which allow the brain to generate adequate and flexible behaviour. Here, we address its role in mediating behavioural adjustments that aid in coping with acutely threatening environments. For this we combine optogenetic manipulation of pituitary corticotroph cells in larval zebrafish with newly developed assays for measuring goal-directed actions in very short timescales. Our results reveal modulatory actions of corticotroph cell activity on locomotion, avoidance behaviours and stimulus responsiveness directly after the onset of stress. Altogether, the findings uncover the significance of endocrine pituitary cell…

0301 basic medicinemedicine.medical_specialtyScienceGeneral Physics and AstronomyBiologyStimulus (physiology)OptogeneticsGeneral Biochemistry Genetics and Molecular BiologyArticleAnimals Genetically Modified03 medical and health sciencesAnterior pituitaryInternal medicinemedicineZebrafish larvaeAvoidance LearningEndocrine systemAnimalsCorticotrophsZebrafishQLMultidisciplinaryQGeneral ChemistryCorticotroph CellOptogenetics030104 developmental biologyEndocrinologymedicine.anatomical_structureCorticotropic cellNeuroscienceLocomotionStress PsychologicalHormone
researchProduct

The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency

2016

The visceral adiposity index, based on anthropometric and metabolic parameters, has been shown to be related to adipose tissue function and insulin sensitivity. We aimed to evaluate the performance of the visceral adiposity index in adult patients with growth hormone deficiency. We enrolled 52 patients(mean age 51 ± 13 years) with newly diagnosed growth hormone deficiency and 50 matched healthy subjects as controls at baseline. At baseline and after 12 and 24 months of treatment we evaluated anthropometric measures, lipid profile, glucose and insulin during an oral glucose tolerance test, hemoglobin A1c, homeostasis model assessment estimate of insulin resistance, quantitative insulin sensi…

AdenomaAdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipose tissue030209 endocrinology & metabolism030204 cardiovascular system & hematologyGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansPituitary NeoplasmsInsulin-Like Growth Factor IDwarfism PituitaryAdiposityAgedmedicine.diagnostic_testbusiness.industryInsulinQuantitative insulin sensitivity check indexMiddle Agedmedicine.diseaseGrowth hormone treatmentEndocrinologygrowth hormoneFemaleInsulin ResistanceWaist CircumferencebusinessLipid profile
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical & Gynecological Survey
researchProduct

Early Lung Function Abnormalities in Acromegaly.

2014

BACKGROUND: Acromegaly is an insidious disorder caused by a pituitary growth hormone (GH)-secreting adenoma resulting in high circulating levels of GH and insulin-like growth factor I (IGF-I). Respiratory disorders are common complications in acromegaly, and can severely impact on quality of life, eventually affecting mortality. OBJECTIVES: The present study aimed to explore structural and functional lung alterations of acromegalic subjects. METHODS: We enrolled 10 consecutive patients (M/F: 5/5) affected by acromegaly. In all patients, magnetic resonance imaging (MRI) revealed the presence of pituitary tumor. All patients underwent clinical, lung functional, biological, and radiological as…

AdultLung DiseasesMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTime FactorsAdenomaVital CapacitySettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyspirometry dyspnea acromegalySettore MED/13 - EndocrinologiaPredictive Value of TestsDLCOForced Expiratory VolumeDiffusing capacityInternal medicineAcromegalymedicineHumansLung volumesRespiratory systemLungAgedLungbusiness.industryPituitary tumorsMiddle Agedrespiratory systemmedicine.diseaseMagnetic Resonance Imagingrespiratory tract diseasesRadiographyEarly Diagnosismedicine.anatomical_structureCase-Control StudiesPulmonary Diffusing CapacityFemaleGrowth Hormone-Secreting Pituitary AdenomaLung Volume Measurementsbusiness
researchProduct

The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients

1995

Roxindole is a potent autoreceptor-selective dopamine agonist with additional properties as a serotonin reuptake inhibitor and 5-HT1A agonist. In order to get more insight into its mode of action in various psychiatric populations, we evaluated the effects of subchronic roxindole treatment on pituitary and adrenal hormone secretion, i.e. release of prolactin, thyroid stimulating hormone (TSH), growth hormone (GH), luteinizing hormone (LH), and cortisol. Fifteen schizophrenic patients with positive and negative symptomatology, respectively, were treated with roxindole for 28 days. Both basal and thyrotropin releasing hormone (TRH) -induced prolactin secretion diminished significantly to 26.4…

AdultMaleendocrine systemmedicine.medical_specialtyIndolesHydrocortisoneendocrine system diseasesPyridinesThyrotropinThyrotropin-releasing hormonePharmacologyDopamine agonistchemistry.chemical_compoundThyroid-stimulating hormoneAnterior pituitaryRoxindoleInternal medicinemedicineHumansPharmacologybusiness.industryLuteinizing HormoneMiddle AgedProlactinGrowth hormone secretionOxindolesProlactinEndocrinologymedicine.anatomical_structurechemistryGrowth HormoneDopamine AgonistsSchizophreniaFemaleSchizophrenic PsychologyLuteinizing hormonebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugPsychopharmacology
researchProduct

Neuroendocrine response to antipsychotics: effects of drug type and gender

1999

Abstract Background: To study the influences of drug type and gender on the neuroendocrine response to neuroleptic treatment, we compared the endocrine actions of two neuroleptics with different receptor affinity profiles—a substituted benzamide, amisulpride, a selective D 2 -like dopamine antagonist; and a thioxanthene, flupenthixol, a mixed D 1 /D 2 -like antagonist also blocking serotonin, H 1 , and D 1 receptors—on anterior pituitary hormone secretion in schizophrenic patients (DSM-III-R). Methods: Blood was withdrawn at 15-min intervals to assess basal secretion of prolactin, growth hormone (GH), and thyroid-stimulating hormone (TSH). Four hundred micrograms of thyrotropin-releasing ho…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesThyrotropinThyrotropin-releasing hormoneFlupenthixolPharmacologySex FactorsDouble-Blind MethodAnterior pituitaryThyroid-stimulating hormoneInternal medicinemedicineHumansAmisulprideBiological PsychiatryHuman Growth Hormonebusiness.industryDopamine antagonistNeurosecretory SystemsProlactinProlactinFlupenthixolmedicine.anatomical_structureEndocrinologySchizophreniaFemaleSchizophrenic PsychologyAmisulprideSulpiridebusinesshormones hormone substitutes and hormone antagonistsAntipsychotic Agentsmedicine.drugHormoneBiological Psychiatry
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct